Related Experiment Video

Updated: Feb 24, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.7K

KCNJ11 and KCNQ1 Gene Polymorphisms Are Not Associated with Post-Transplant Diabetes Mellitus in Kidney Allograft

E Dabrowska-Zamojcin1, M Tarnowski2, M Szydlowski2

  • 1Department of Pharmacology, Pomeranian Medical University, Szczecin, Poland.

Folia Biologica
|August 15, 2017
PubMed

Insights

This study found no link between KCNJ11 and KCNQ1 gene variations and post-transplant diabetes mellitus (PTDM) in Polish kidney transplant patients. These findings suggest these specific gene polymorphisms do not influence PTDM risk in this population.

Area of Science:

  • Genetics
  • Endocrinology
  • Transplantation

Background:

  • Post-transplant diabetes mellitus (PTDM) is a common complication after solid organ transplantation, often linked to calcineurin inhibitor therapy.
  • ATP-sensitive potassium channels, encoded by KCNJ11 and KCNQ1, are crucial for insulin secretion and diabetes development.
  • Previous research indicates associations between KCNJ11 and KCNQ1 gene polymorphisms and type 2 diabetes.

Purpose of the Study:

  • To investigate the association between KCNJ11 and KCNQ1 gene polymorphisms and the incidence of PTDM in kidney allograft recipients.
  • To evaluate the role of these gene variants in the context of tacrolimus treatment.

Main Methods:

  • A cohort of 201 kidney transplant recipients treated with tacrolimus was studied.
  • Patients were categorized into two groups: those with PTDM (N=35) and those without (N=166).
  • Univariate Cox regression models (additive, dominant, recessive) were employed to analyze the association between KCNJ11/KCNQ1 polymorphisms and PTDM.

Main Results:

  • No statistically significant associations were found between KCNJ11 and KCNQ1 gene polymorphisms and PTDM across all three tested models.
  • The study did not identify a genetic link between these specific potassium channel gene variants and the development of PTDM in the studied cohort.

Conclusions:

  • The findings suggest that KCNJ11 and KCNQ1 gene polymorphisms are not associated with post-transplant diabetes mellitus in kidney transplant recipients treated with tacrolimus within the Polish population.
  • Further research may be needed to explore other genetic or environmental factors contributing to PTDM in this patient group.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K
Measurement of T Cell Alloreactivity Using Imaging Flow Cytometry09:04

Measurement of T Cell Alloreactivity Using Imaging Flow Cytometry

Published on: April 19, 2017

14.0K

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
562
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
527
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
33
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
68